Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Many patients with chronic kidney disease (CKD) require anticoagulation or antiplatelet therapy for conditions like atrial fibrillation or coronary artery disease.
• Traditional treatments include vitamin K antagonists (VKAs) and platelet aggregation inhibitors.
• Direct oral anticoagulants (DOACs) offer an alternative, but their renal elimination necessitates careful consideration in CKD patients.

Purpose of the Study:

• To review the safety and efficacy of DOACs compared to VKAs, heparins, and heparinoids in patients with CKD.
• To discuss special considerations for using DOACs in patients with impaired renal function.
• To evaluate the impact of varying estimated glomerular filtration rates (eGFR) on DOAC use.

Main Methods:

• Review of existing literature and clinical data on DOAC use in CKD patients.
• Comparison of DOACs with traditional anticoagulants (VKAs, heparins, heparinoids).
• Analysis of safety and efficacy based on patient eGFR levels.

Main Results:

• DOACs are safe and more effective than VKAs in patients with eGFR > 60 mL/min.
• In CKD stage 3, DOACs show comparable efficacy to VKAs with a reduced bleeding rate.
• The benefits of DOACs diminish as renal function declines; avoidance is recommended for eGFR < 30 mL/min, especially for renally cleared DOACs.
• DOACs appear safe for use in older patients.

Conclusions:

• DOACs represent a valuable therapeutic option for anticoagulation in CKD patients, particularly those with preserved renal function.
• Dosing and selection of DOACs must be individualized based on eGFR to optimize safety and efficacy.
• Further research may be needed to refine guidelines for DOAC use in advanced stages of CKD.